Literature DB >> 21397523

Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland.

Qian Wang1, Jue-qian Zhou, Lie-min Zhou, Zi-yi Chen, Zi-yan Fang, Shu-da Chen, Li-bai Yang, Xiao-dong Cai, Qi-lin Dai, Hua Hong, Hong-xuan Wang.   

Abstract

Previous studies have found a strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome in Asian areas including Taiwan, Hongkong and Thailand. This study explores the association between HLA-B*1502 allele and carbamazepine-induced cutaneous adverse reactions in Han Chinese of southern China mainland, and find the genetic marker that can predict carbamazepine-induced cutaneous adverse reactions. HLA-B*1502 allele genotyping was performed by a polymerase chain reaction-sequence specific primers (PCR-SSP) method in 48 Han Chinese subjects who had carbamazepine-induced cutaneous adverse reactions, including 9 severe cutaneous adverse reaction patients with Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) and 39 cutaneous adverse reaction patients with maculopapular eruption (MPE). Meanwhile 80 carbamazepine-tolerant controls and 62 healthy individuals were also tested. The frequency of HLA-B*1502 allele among SJS/TEN patients (100%) is significantly higher than carbamazepine-tolerant controls (13.75%, P<0.001) and healthy individuals (17.74%, P<0.001). But the frequency between MPE patients and carbamazepine-tolerant controls (25.64% vs.13.75%, P=0.110) did not have any significant difference. The data showed that HLA-B*1502 allele is strongly associated with carbamazepine-induced SJS/TEN but not MPE in Han Chinese of southern China mainland.
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397523     DOI: 10.1016/j.seizure.2011.02.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  36 in total

Review 1.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

2.  External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy.

Authors:  Guigao Lin; Kuo Zhang; Yanxi Han; Jiehong Xie; Jinming Li
Journal:  J Clin Lab Anal       Date:  2017-04-25       Impact factor: 2.352

3.  Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population.

Authors:  C-C Chang; C-C Ng; C-L Too; S-E Choon; C-K Lee; W-H Chung; S H Hussein; K-S Lim; S Murad
Journal:  Pharmacogenomics J       Date:  2016-03-01       Impact factor: 3.550

4.  Screening for 392 polymorphisms in 141 pharmacogenes.

Authors:  Jason Yongha Kim; Hyun Sub Cheong; Tae-Joon Park; Hee Jung Shin; Doo Won Seo; Han Sung Na; Myeon Woo Chung; Hyoung Doo Shin
Journal:  Biomed Rep       Date:  2014-04-30

Review 5.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

6.  Pharmacogenomics--how close/far are we to practising individualized medicine for children?

Authors:  Chor-Wing Sing; Ching-Lung Cheung; Ian C K Wong
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 7.  The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review.

Authors:  Nahoko Kaniwa; Yoshiro Saito
Journal:  Ther Adv Drug Saf       Date:  2013-12

8.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

9.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 10.  Genotyping for severe drug hypersensitivity.

Authors:  Eric Karlin; Elizabeth Phillips
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.